Welcome and introduction of participants

Welcome and introduction to ANL and overview of resources (Talk/presentation).

Overview and progress of the Disease X vaccine library approach and strategy-5 year objectives

Overview of high-level plans from HMRI, including resources and capacity for immunogen design

Overview of high-level plans from IDDL, including resources and capacity for immunogen design

Process for coordination between IDDL and HMRI and within HMRI consortium (HMRI/IDDL). Database storage and controlled access. VIPNetX/ANL database

Review of process for T-cell immunogen design, antigen verification & down selection criteria and update on work packages

Review of ANL workflow and progress update

Review of Spillover program

Recap of day 1, objectives for day 2

• Tim Endy
• Ann-Muriel Steff

Junin virus vaccine designs update: vaccine composition, immunogens, timings and number of designs and preclinical work

Lassa virus vaccine designs: immunogen design, progress with SK bio Milestones/criteria for down-selection and/or optimization in immunogen design • At the stage of immunogen design by HMRI & IDDL • At the stage of transfer of the candidates to SK (i.e. elicitation of neutralizing antibodies and/or expression efficiency) • Results to date

Update on H5N1 designs

Patents and IP, tools for the Global South Discussion

Project Management Discussion Reporting, JMAG, other CEPI follow-up (Polina) Interactions with future developers

Tour of ANL

Summary from breakout groups and meeting closure